Canaccord Genuity Covers Eloxx Pharmaceuticals (ELOX) with $24 Target; 1 Analysts Covering Toyota Motor (TM)

June 29, 2018 - By Jerrie Dane

Toyota Motor Corporation (NYSE:TM) Logo

Professional analysts at Canaccord Genuity initiated coverage on Eloxx Pharmaceuticals (ELOX) with a Buy rating. The target for ELOX is exactly $24. It gives a potential upside of 30.93% from firm’s last stock close.

Among 3 analysts covering Toyota Motor Corporation Common Stock (NYSE:TM), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Toyota Motor Corporation Common Stock had 4 analyst reports since March 1, 2018 according to SRatingsIntel. The stock of Toyota Motor Corporation (NYSE:TM) has “Neutral” rating given on Thursday, March 1 by Bank of America. The stock of Toyota Motor Corporation (NYSE:TM) has “Hold” rating given on Wednesday, April 11 by Jefferies. The rating was upgraded by Goldman Sachs to “Buy” on Saturday, June 2. The stock of Toyota Motor Corporation (NYSE:TM) earned “Buy” rating by Goldman Sachs on Monday, June 4. See Toyota Motor Corporation (NYSE:TM) latest ratings:

04/06/2018 Broker: Goldman Sachs Old Rating: Neutral New Rating: Buy Upgrade
02/06/2018 Broker: Goldman Sachs Rating: Buy Upgrade
11/04/2018 Broker: Jefferies Rating: Hold New Target: $129.5200 Maintain
01/03/2018 Broker: Bank of America Old Rating: Underperform New Rating: Neutral Upgrade

More notable recent Toyota Motor Corporation (NYSE:TM) news were published by: 247Wallst.com which released: “Ford Sales Expected to Drop in June” on June 28, 2018, also Seekingalpha.com with their article: “Data grab by Toyota” published on June 20, 2018, Seekingalpha.com published: “Auto tariff would mean $45B in higher costs for US consumers, group says” on June 26, 2018. More interesting news about Toyota Motor Corporation (NYSE:TM) were released by: Finance.Yahoo.com and their article: “Market Morning: Futures Down, Oil Up, China Crashing, Boeing Goes Hypersonic, Tariffs Galore” published on June 28, 2018 as well as Bizjournals.com‘s news article titled: “Former P&G executive joins C-suite of Toyota” with publication date: June 27, 2018.

Toyota Motor Corporation designs, manufactures, assembles, and sells passenger vehicles, minivans and commercial vehicles, and related parts and accessories. The company has market cap of $193.13 billion. The firm operates through Automotive, Financial Services, and All Other divisions. It has a 8.56 P/E ratio. It offers hybrid cars under the Prius, Voxy/Noah, NX300h, RC300h, Esquire, Alphard, Vellfire, Sienta, RX-HV, Auris, C-HR, and LC names; fuel cell passenger vehicles under the MIRAI name; and conventional engine vehicles, including subcompact and compact cars under the Corolla sedan, Yaris, Vitz, Aygo, Corolla Axio/Fielder, Porte, Spade, Auris, Etios, Vios, AGYA, and Yaris iA brand names.

The stock increased 1.56% or $1.98 during the last trading session, reaching $129.09. About 173,439 shares traded. Toyota Motor Corporation (NYSE:TM) has risen 21.12% since June 29, 2017 and is uptrending. It has outperformed by 8.55% the S&P500. Some Historical TM News: 19/04/2018 – Pickup Truck Market in the US 2018-2022 – Key Vendors are Fiat Chrysler, Ford, General Motors, Honda, Nissan & Toyota – ResearchAndMarkets.com; 15/03/2018 – TOYOTA SAYS IT HASN’T MADE A DECISION ON BUYING UBER’S SOFTWARE; 12/04/2018 – Volkswagen Truck teams with Toyota’s Hino despite parents’ rivalry; 09/05/2018 – Toyota Motor Raises FY Dividend to Y220.00 Vs Y210.00; 16/04/2018 – TOYOTA,LEXUS TO START DEPLOYING DSRC SYSTEMS ON ’21 US VEHICLES; 21/04/2018 – CarScoops: Toyota Confirms The Reborn Supra Will Use A BMW-Sourced Engine; 09/05/2018 – Toyota Motor FY Net Y2.49T Vs Net Y1.83T; 19/04/2018 – Moody’s Upgrades Class B Notes Of Toyota Glory 2017 Phase Ii Auto Loan Credit Asset-backed Securities; 08/05/2018 – TABLE-Misawa Homes 1722.T -2017/18 parent results; 19/03/2018 – Volvo, Toyota Steering Clear of Questions on Uber Crash’s Impact

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. The company has market cap of $612.72 million. The Company’s lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. It currently has negative earnings.

The stock decreased 1.29% or $0.24 during the last trading session, reaching $18.33. About 261,039 shares traded or 38.37% up from the average. Eloxx Pharmaceuticals, Inc. (ELOX) has risen 234.17% since June 29, 2017 and is uptrending. It has outperformed by 221.60% the S&P500. Some Historical ELOX News: 14/05/2018 – lncysus Announces Appointment of Joy Bessenger as Senior Vice President, Finance and Strategy; 17/05/2018 – Seres Therapeutics to Host Microbiome R&D Event and Webcast on May 24, 2018; 14/05/2018 – Soleno Therapeutics Announces Initiation of Phase lll Clinical Trial of DCCR in Prader-Willi Syndrome; 10/05/2018 ELOXX PHARMACEUTICALS INC ELOX.O – QTRLY SHR LOSS $0.31

More notable recent Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) news were published by: Streetinsider.com which released: “Canaccord Genuity Starts Eloxx Pharma (ELOX) at Buy, ‘Lead read-through therapeutic candidate ELX-02 promising'” on June 29, 2018, also Nasdaq.com with their article: “Eloxx Expands Leadership Team with Two Global Pharmaceutical Executives to Accelerate Growth” published on June 25, 2018, Streetinsider.com published: “UPDATE: SunTrust Robinson Humphrey Starts Eloxx Pharma (ELOX) at Buy” on June 25, 2018. More interesting news about Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) were released by: Nasdaq.com and their article: “Eloxx Appoints Global Pharmaceutical Leader, Neil Belloff, Executive Vice President, General Counsel and Corporate …” published on June 18, 2018 as well as Seekingalpha.com‘s news article titled: “Key events next week – healthcare” with publication date: June 01, 2018.

Among 3 analysts covering Eloxx Pharmaceuticals (ELOX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Eloxx Pharmaceuticals has $26 highest and $2000 lowest target. $22’s average target is 20.02% above currents $18.33 stock price. Eloxx Pharmaceuticals had 3 analyst reports since May 1, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Friday, June 8 by Piper Jaffray.